

CURRICULUM VITAE

Peter D'Arcy Sutherland

MBBS, FRACS

November, 2010

Peter Sutherland

Curriculum Vitae

- 2 -

Name Dr Peter D'Arcy Sutherland MBBS, FRACS (Urology)
Provider number: I03833A

Address (Work) 326 South Terrace,
ADELAIDE SA 5000
Phone: 08 8223 1472
Fax: 08 8232 3316
Email: psutherland@sturology.com.au

Nationality Australian

ACADEMIC RECORD

Primary School St Peter's College, Adelaide

Secondary School St Peter's College, Adelaide

1969 Matriculation.
St Peter's College, Adelaide

1970-1975 Commenced at University of Adelaide Medical School

1976 Graduated MBBS

1977 Passed Primary Surgical Examination,
FRACS

1982 Passed Fellowship in Urology Examination
Melbourne, Australia.

1982 Gained Fellowship in Urological Surgery

APPOINTMENTS HELD

1976	Internship Royal Adelaide Hospital
1977-1978	Basic Surgical Training, Royal Adelaide Hospital
1979	Appointed to Urological Training Post, Royal Adelaide Hospital
1980-1981	Advanced Trainee (Urology), Royal Adelaide Hospital under the guidance of Mr John Maddern, (Head of Unit 1980-1981).
1982	Advanced Trainee (Urology), Flinders Medical Centre under the guidance of Professor Villis Marshall.
1983	Appointed to Institute of Urology, London as Clinical Assistant with Dean of the Institute, Mr John Pryor. This Fellowship was principally in the area of Andrology which was Mr Pryor's main area of interest.
1984	Appointed to UCLA Medical Centre as a Foreign Fellow under the guidance of Dr J Kauffmann, Chief of Urology. Again, the main focus of this appointment was in the area of Andrology.
1985-1989	Appointed as a Visiting Medical Specialist in Urology at Flinders Medical Centre, Adelaide under the guidance of Professor Villis Marshall.
1989-1995	Appointed as a Senior Visiting Medical Specialist in Urology at the Royal Adelaide Hospital, Adelaide.
1995-present	Appointed as Head of the Urology Unit at the Royal Adelaide Hospital, Adelaide.
1985-present	Commenced private practice in Adelaide, South Australia. Principal interests include Andrology and Prostate Disease. The practice has set up Australasia's first private specialist day surgery managing only urological conditions.

MAIN LEISURE ACTIVITIES

Sport – Golf

Arts - Opera

PROFESSIONAL REGISTRATIONS AND MEMBERSHIPS

South Australian Medical Board, Registered since 1977

Royal Australasian College of Surgeons, Fellow since 1983

BOARDS and POSITIONS HELD

1988 President of the Urological Society in South Australia.

1987-1992 Appointed to the Australasian Board of Urology.

1998-present National Advisory Board Member for:
Pfizer and Viagra,
Pharmacia and Caverject,
Abbott and Uprima,
Eli Lilly and Cialis,
AMS and their penile prosthetic devices
Bayer-GSK and Levitra.
Astra Zeneca, Zoladex and Cosudex
Device Technology and the daVinci Robot

2004 Principal Surgeon, Robotic Surgical Programme,
Royal Adelaide Hospital.

2005 Mentor surgeon, Robotic Surgical Programme,
Royal Adelaide Hospital, Australia.

2006 Mentor surgeon, Robotic Surgical Programme,
St Vincent's Hospital, Sydney, Australia.

2007 Mentor surgeon, Robotic Surgical Programme,
St Vincent's Hospital, Sydney, Australia.

Mentor surgeon, Robotic Surgical Programme,
Tauronga Hospital, New Zealand.

2008 Mentor surgeon, Robotic Surgical Programme,
John of God Hospital, Perth, Australia.

Mentor surgeon, Robotic Surgical Programme,
Royal Adelaide Hospital, Australia.

Mentor surgeon, Greenslopes Private Hospital.

Peter Sutherland

Curriculum Vitae

- 5 -

2009 Mentor Surgeon, Greenslopes Private Hospital.

MEMBERSHIPS

Urological Society of Australasia
Prostate Cancer Foundation of Australia
Australian Prostate Collaboration
International Society of Sexual Medicine
Societe Internationale d'Urologie
Society of Robotic Surgery – Charter Member

INVITED SPEAKER

Urological Society of Malaysia
Urological Society of Taiwan
Urological Society of Korea
Urological Society of Vietnam
World Robotic Institute, Orlando, Florida

WORKING GROUPS

Andrology Australia
ASERNIPS
Australian Prostate Cancer Bio-Resource Consortium

PRESENTATIONS

2005 Asia-Pacific Society for Sexual & Impotence Research

2007 Men's Health Promotion Forum

2008 Prostate Cancer Foundation of Australia –
DVD – 'A guide for men & their partners living
with prostate cancer'

2009 Men's Health Speaker Program – Prostate Cancer
Foundation of Australia.

PRINCIPAL INVESTIGATOR IN THE FOLLOWING TRIALS

PFIZER A3711044 – A multi-center, randomized, parallel group, double-blind, placebo controlled proof of concept and dose ranging study with an active control to assess the efficacy and safety/tolerability of UK-369,003 immediate release (IR) and modified release (MR) in the treatment of men with lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED).

Pfizer A1481119 – An International, Multicenter, Randomized, Parallel Group, Double-blind, Placebo-Controlled, Flexible Dose Escalation Study to Evaluate Self-Esteem and Overall Relationships in Men with Erectile Dysfunction Treated with Viagra (sildenafil citrate)

Lilly H6D-MC-LVHG-2007 – A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, 5-Group Multinational Study to Evaluate the Efficacy, Dose Response, and Safety of Tadalafil Once-a-Day Dosing for 12 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia.

PPD SP583- A Phase 3, Parallel Group, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled Multicenter Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects with Overactive Bladder Syndrome.

PPD Yamanouchi Tamsulosin Study –Tamsulosin with Benign Prostatic Hyperplasia (02-OMN-02)

Pfizer A1371041- Darifenacin in UUI - A1371041 long term, open label, Multicentre study of darifenacin in subjects with overactive bladder.

Novartis A1371042 – Darifenacin Extension Study – A long-term open label, multicentre study of darifenacin in subjects with overactive bladder (urge Urinary Incontinence).

Pfizer A1371013 - Darifenacin

Pfizer A3871014 – UK-390,957 in Premature Ejaculation

Pfizer A3711030- UK-369,003 in Erectile Dysfunction

Eli Lilly H6D- VI- LVFH : Switching from Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference.

Pfizer A1481195 – Viagra Erectile Dysfunction

Pfizer A3871027 – A Phase 2B, Multi-Centre, Double-blind, Placebo-controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men with Premature Ejaculation.

GSK Vardenafil SB-7825258-001- A randomised, double-blind, parallel-group, placebo-controlled study evaluating the efficacy and safety of vardenafil administered for 12 weeks in flexible-dose regimen compared to placebo in male erectile dysfunction subjects of broad etiology previously unresponsive to sildenafil therapy by history.

Pfizer A3871028 – A Phase 2 multi-centre, open-label, long-term extension trial to assess the safety of oral UK-390,957, administered as required in adult men with premature ejaculation.

Urogene OAB study- A multi-centre, randomised, double-blind, parallel group, Phase II Efficacy Study of HP749 20mg twice-daily versus placebo in patients with overactive bladder (OAB).

GSK ARI40006 – A randomized, double-blind, placebo-controlled, parallel group study of the efficacy and safety of Dutasteride 0.5mg administered once daily for four years to reduce the risk of biopsy-detectable prostate cancer.

Bayer – Potent II 12094 - Pivotal phase III trial to investigate the efficacy and safety of an Orodispersible Tablet vardenafil versus placebo in the treatment of men with Erectile dysfunction (ED) – a fixed-dose, double-blind, randomized multi-centre Trial – **POTENT II**

Novartis CZOL446E2432- Zometa for androgen-sensitive advanced prostate cancer – the Zometa ASAP Trial.

CURRENT TRIALS – PRINCIPAL INVESTIGATOR

Eli Lilly H6D-CR-S024 – A Comparison of Psychosocial Outcomes Following Tadalafil Once a Day or PDE5 Inhibitor As Needed in Men with Erectile Dysfunction.

Allergan 191622-082-01- A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment.

Eli Lilly H6D-MC-LVID – A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Global Multicenter Study to evaluate the efficacy and safety of Tadalafil once daily dosing for 12 weeks in men with signs and symptoms of Benign Prostatic Hyperplasia.

Eli Lilly IIA-MC-BPAE(a) – A phase 2, Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 Weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (BPH).

PUBLICATIONS

1. Sutherland PD, Matson PL, Masters JR, Pryor JP.

Association between infertility following reversal of vasectomy and the presence of sperm agglutinating activity in semen.

Int J Androl. 1984 Dec;7(6):503-8.

2. Sutherland PD, Maddern JP, Jose JS, Marshall VR.

Urethral stricture after cardiac surgery.

Br J Urol. 1983 Aug;55(4):413-6.

3. Sutherland PD, Landon GV, Matson PL, Pryor JP.

Round headed sperm.

Br J Urol. 1985 Aug;57(4):486. No abstract available.

4. **Sutherland PD, Howard PR, Marshall VR.**
Colonic infarction following ethanol embolisation of the kidney.
Br J Urol. 1986 Jun;58(3):337. No abstract available.
5. **Gallus A, Murphy W, Nacey J, Morris M, Sutherland P, Marshall V, Magnani H.**
The influence of Org 10172, and antithrombotic heparinoid, on urinary blood loss after transurethral prostatectomy.
Thromb Res. 1989 Oct 15;56(2):229-38.
6. **Maddern GJ, Sutherland PD.**
Laparoscopic exploration for a presumed intra-abdominal testicle.
Endosc Surg Allied Technol. 1994 Dec;2(6):293.
7. **Ricciardelli C, Quinn DI, Raymond WA, McCaul K, Sutherland PD, Stricker PD, Grygiel JJ, Sutherland RL, Marshall VR, Tilley WD, Horsfall DJ.**
Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer.
Cancer Res. 1999 May 15;59(10):2324-8.
8. **Tooher R, Sutherland P, Costello A, Gilling P, Rees G, Maddern G.**
A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia.
J. Urol. 2004 May;171(5):1773-81.
9. **McMahon CG, Stuckey BG, Lording DW, Wittert GA, Murphy A, Shin J, Sutherland PD, Palmer NR, Lowy MP, Jesudason DR, Fredlund P.**
A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men.
Int J Clin Pract. 2005 Feb;59(2):143-9.
10. **Borg M, Sutherland P, Stapleton A, Bolt J, Steele D, Landers B, Porter A, Buxton S, Heilborn C, Wong HZ.**
Outcome of post-prostatectomy radiotherapy in one institution.
Australas Radiol. 2006 Oct;50(5):475-80.
11. **Lowy M, Collins S, Bloch M, Gillman M, Lording D, Sutherland P, Wang H, Stecher V.**
Quality of erection questionnaire correlates: change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction.
J Sex Med. 2007 Jan;4(1):83-92.
12. **Ludbrook G, Sutherland P.**
Erroneous pulse oximetry readings during robotic prostatectomy
Anaesth Intensive Care. 2007 Feb; 35(1):144-5.
13. **Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L.**
Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia.
Eur Urol. 2009 Apr 22. [Epub ahead of print]